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Abstract
As gene therapies continue to be developed, the role played by siRNA
technologies in anti-cancer regimens seems likely to increase. And, as siRNA
technologies continue to be studied, the use of gold nanoparticle conjugate systems to
deliver siRNA in vivo will proliferate as well. In light of this trend in cancer therapeutics,
this project aimed to design a AuNP carrier for siRNA. With the goal of creating an
efficient base from which effective siRNA-AuNP conjugates could be synthesized, the
development of C12PEI coated AuNPs was closely investigated. Toward this end, AuNPC12PEI conjugates were synthesized with an average diameter of 25 nm, an average zeta
potential of +58 mV, and an average of 258 C12PEI units per AuNP. Additionally,
C12PEI-AuNPs were successfully conjugated with tRNA in preparation for siRNA
binding studies.
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Chapter 1: Introduction
RNA interference, or RNAi, is a recently discovered mechanism by which
specific genes are silenced in a target cell, tissue, or organism. The silencing effect has
been attributed to the cleavage of mRNA by an enzymatic complex activated by the
presence of small interfering RNA, or siRNA, that is complementary to the mRNA
sequence. By cleaving the pre-translational mRNA, the protein encoded by the target
gene will not be synthesized, essentially “silencing” the expression of the gene.
The interest in gene silencing is multifaceted; as the understanding of RNAi has
progressed, multiple opportunities for application have become evident. In early studies,
introduction of exogenous RNA was used to observe and document the function of genes
in a variety of organisms.1-3 Many contemporary projects are exploring the advantage of
using RNAi as a mechanism for gene therapy. In this context, cancer therapeutics are
being investigated intensely.3-11
Although much is known about the mechanism of the RNAi pathway, more
research is needed to investigate both the delivery of siRNA to targeted cells, and the
precision and efficiency of gene knockdown if steps toward therapeutic regimens are to
be made. In the area of siRNA delivery, several promising methods of delivery are being
developed. One method being explored by numerous research groups during the past
decade is based on gold nanoparticles.12 Regardless of the system being investigated,
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optimizing the method used to target specific cells, the mode of conjugation of siRNA to
the vehicle, and the release of siRNA once inside the target cell is crucial to progress
toward clinical trials in cancer treatment. In the area of gene knockdown, further research
must be done to isolate siRNA sequences that can negatively affect genes essential to
tumor vitality without creating adverse effects in the rest of the genome. Also, additional
studies may improve the understanding of factors that control the efficiency of gene
knockdown in vivo.
As such, for the purposes of this project, the goal of utilizing RNAi was the
development of novel cancer therapy agents, specifically AuNP-based nanoparticles, that
display high efficiency and limited side effects. This project, in conjunction with the
Huang research group, sought to develop an siRNA delivery vehicle that reduces the
hindrances described above: non-specific delivery, inadequate potency, and low
efficiency. Using AuNPs, a layered approach to synthesis was implemented, similar to
the approaches of Elbakry et al. (2009) and J.S. Lee et al. (2009) described below. In
anticipation of producing a therapeutic agent that could equal or surpass the benchmark
of 80% gene knockdown achieved by Heidel et al. (2007), as reported below, significant
attention was given to the first stage of nanoconjugate development involving the
conjugation of C12PEI to the AuNP surface in an efficient manner. Due to the exploratory
nature of this design project, no definitive hypothesis was able to be tested. Rather, a
consistent synthetic platform was attempted from which future, hypothesis-driven
optimization could be performed.
1

Chapter 2. Literature Review
Various approaches have been used in the process of researching cancer
therapeutics using RNAi. In general, each approach consists of two broad focal points:
the gene target, and the mode of delivery. For example, in reference to gene targets,
Kittler et al. (2004) suggest that genes associated with cell division are plausible targets
for accomplishing tumor suppression. Screening for genes that, upon suppression, cause
arrest of mitosis, defects in the spindle structure, or lead to cell death, they determined
that at least 37 genes are essential for cell division. Six of these genes, one of which
being RRM2, were determined to cause cell death at the entrance into mitosis.4
RRM2 refers to the second of two required subunits of the ribonucleotide
reductase (RR) enzyme. RR is an important enzyme in the mitotic pathway because it
catalyzes

the

reduction

of

ribonucleotides

to

their

corresponding

2’-

deoxyribonucleotides, which are essential for DNA synthesis and replication. Of the two
subunits, RRM1 is expressed at a maintained level throughout the entire cell cycle, while
RRM2 is only expressed leading up to mitosis. Two groups, Heidel et al. (2007) and Reid
et al. (2009), have presented research concerning the potential effect of RR knockdown.
Although each group reports RR as a useful target, the groups differ on which subunit is
selected for suppression.5,6
2

Heidel et al. focus on the RRM2 subunit because it is over expressed in cancer
cells and has been shown to adversely affect tumor cell growth. In summary, Heidel et al.
screened computer databases for potential RRM2 target sequences and tested three
preliminary siRNAs, eventually refining the siRNA sequences to determine the siRNA
with greatest knockdown potential. After identifying the most successful siRNA through
in vitro studies (siR2B+5, 80% knockdown), the team probed its knockdown potential in
vivo and monitored the viability of infected organisms. The positive results yielded in
vivo led to the conclusion that RRM2 knockdown by siR2B+5 is a potential candidate for
further study. Importantly, Heidel et al. noted that RRM2 knockdown in tumor tissues
showed no observable adverse effects in the organism.5
In contrast, Reid et al. focus on the RRM1 subunit, comparing RRM1 knockdown
to RRM2 knockdown in equivalent cells. Reid’s group demonstrates the efficiency of
tumor growth suppression by siRNAs targeting either RRM1 or RRM2. However, their
findings indicate that the siRNAs targeting RRM1 are somewhat more potent than
equimolar concentrations of those targeting RRM2. A possible explanation given for the
difference in potency is the apparently higher abundance at which RRM2 is expressed
versus RRM1 in cells. Reid et al. also demonstrate that minor suppression, that is,
suppression insufficient for cell death, of either RRM1 or RRM2 may cause tumor cells
to become sensitive to other drugs, such as hydroxyurea.6
When the findings of these groups, Heidel et al. and Reid et al., are compared, a
trade off is seen in the choice of which RR subunit to suppress. On one hand, RRM1
3

knockdown is more potent than RRM2 knockdown.6 On the other hand, RRM2 is over
expressed in cancer cells and knockdown has minimal adverse effects in other tissues.5
As mentioned above, the second major aspect of researching cancer therapeutics
is the mode of delivery. In the context of RNAi, siRNA has been delivered virally, or in
conjugation with polymers,10,11 lipid based systems, and nanoparticles.7-9 Although
several options are currently available, the apparent defects associated with each delivery
system are a hindrance to the advancement of RNAi therapy.8 As such, research is being
done in order to provide stability to the siRNA complex,

reduce the lethality of

carriers,7-11 increase the specificity of carriers,10,11 and improve the intracellular release
of siRNA.8,9,11
One promising delivery method, developed by numerous groups throughout the
past decade, seeks to achieve some of these goals through the implementation of gold
nanoparticles (AuNPs),12 which display a high degree of compatibility with living
tissues.8,9 As described by Giljohann et al. (2009), AuNPs are capable of significant
functionalization with siRNA and effectively protect conjugated siRNA from
degradation. The benefit of siRNA conjugation to AuNPs, as reported by Giljohann, is
seen in the more persistent knockdown by siRNA-AuNPs when compared to siRNA
alone.
Another group, Elbakry et al. (2009), implemented a “layer-by-layer” approach to
forming siRNA-AuNP conjugates as a means to facilitate both the cellular uptake of the
conjugated particles and the intracellular release of siRNA. Cellular uptake by
4

endocytosis was enhanced by incorporating polyethylene-imine (PEI) into the siRNAAuNP conjugate particle, which decreased the net negative charge on the particle, and as
a result decreased the repulsion from the cell membrane. Although Elbakry and
coworkers report successful uptake of siRNA-PEI AuNPs, the enhanced stability of the
nanoparticle was found to decrease the intracellular release of siRNA, necessitating the
future implementation of biodegradable polymers capable of facilitating endosomal
release.8
In regard to the incorporation of biodegradable polymers, authors J. S. Lee et al.
(2009) sought to show that the addition of poly(beta-amino ester)s (PBAEs) and inclusion
of disulfide linkages between siRNA and AuNPs would facilitate the uptake and
intracellular release of the siRNA-AuNPs. The group focused on PBAEs that had been
reported to successfully deliver DNA to cells, forming a library of polymers
functionalized with several end groups. In addition to PBAEs, J. S. Lee et al. chose to
attach siRNA to AuNPs via disulfide linkages, which are readily cleavable in the
reducing environment of the cell. Two of the PBAEs tested demonstrated greater
intracellular release (i.e. greater knockdown) than the commercial delivery vehicle
Lipofectamine 2000. Importantly, these findings suggest the necessity of utilizing
biodegradable polymers, as indicated by the absence of delivery when polymers are not
used.9

5

Chapter 3: Experimental Methods
Because of the multifaceted nature of this project, significant attention has been
given the development of successful and repeatable synthetic parameters for AuNP
conjugates before attempting cell studies with siRNA for a gene target, such as RRM2.
As mentioned above, the layer-by-layer synthetic approach chosen closely
resembles the work of other authors, especially Elbakry et al. (2009). Although the
general scheme of coating AuNPs with a layer of cationic polymers, followed by a layer
of nucleic acids, and a final layer of cationic polymers was retained, two important
adjustments to Elbakry’s method should be noted. First, rather than electrostatically
binding the initial layer of PEI to AuNPs that have been pre-coated with 11-mercaptoundecanoic acid (MUA) via thiol chemistry, our group conjugated PEI to MUA prior to
the coating step, allowing the entire molecule (named C12PEI) to interact with the AuNP
surface via thiol chemistry. Additionally, the outer layer of polymers we hope to
implement will include a PEI-PEG copolymer that incorporates a folic-acid receptor
targeting moiety, along with imaging agents needed for cell-studies, rather than PEI
alone. It should also be noted that, due to the relative expense of siRNA when compared
to tRNA, tRNA was selected as a model for siRNA behavior while nanoparticle synthesis
is being optimized.
6

Beginning with the first layer, a replacement of citrate stabilizer with thiolreactive C12PEI, the goal was to develop a protocol that accomplished high PEI coverage,
facile purification, and high recovery yield. To this end, several experiments were
conducted to observe the effects, if any, of the final concentration of C12PEI with respect
to particle stability, size, and recovery yield.
The basic synthetic procedure used

during C12PEI coating is described as

follows. First, a measured volume of C12PEI was delivered to a 14.8 nM solution of
citrate stabilized AuNPs (~15 nm diameter by DLS). After vortexed mixing, the solutions
were allowed to incubate at room temperature for 30 min. Following incubation, a series
of washes by centrifugation and resuspension were performed at 14,000 rpm. The washed
samples were then characterized by UV-Vis spectrophotometry, as well as dynamic light
scattering (DLS), including zeta potential measurements. Final concentrations of 0.5 mM,
1.0 mM, and 2.0 mM C12PEI were examined, along with the method of addition, and the
intensity of washing. With respect to washing, the variables manipulated were the length
of time per wash, and the number of washes per sample. It should be noted that salt
(NaCl) was not added at any point during the synthetic processes.
Along with experiments investigating the effect of the final concentration of
C12PEI, the number of C12PEI units per AuNP was quantified by fluorescence
spectrometry. For this portion of the project, a general fluorophore (fluorescein
isothiocyanate, “FITC”) was selected and incorporated into C12PEI stock prior to
beginning the nanoconjugate synthesis. After completing the final washing step as
7

described above, resuspended conjugates were treated with DTT (dithiothreitol) in order
to reduce the sulfide bonds between the AuNP surface and C12PEI. Following
centrifugation of the DTT-treated solution to remove AuNPs, fluorescence measurements
were taken and compared to the concentration of free C12PEI in the last supernatant in
reference to a standard curve. By relating the concentration of C12PEI released from the
particles to the recovered concentration of AuNPs from the washing procedure, the
number of C12PEI units per AuNP was ascertained.
In addition to the experiments concerning the initial layer of C12PEI, similar work
was done to design a useful protocol for RNA coverage onto AuNP-C12PEI conjugates,
using tRNA as a model system. Again, the goal was to develop a synthetic scheme that
accomplished high RNA coverage (high payload), facile purification, and high recovery
yield. For this step, a net anionic charge was sought as a result of tRNA binding in order
to facilitate electrostatic binding of the next cationic layer. As before, overall size of the
particles was being considered, but the major concerns were particle stability and
monodispersity.
The approach to adding nucleic acids, in this case tRNA, to AuNP-C12PEI
conjugates was carried out in the following manner. First, the volume of tRNA stock
(~26.4k MW, 1 µg/µl) required to achieve the desired final concentration was added to
Ultrapure water. To this aqueous tRNA solution, a smaller volume of AuNP-C12PEI was
added dropwise while vortexing at low speed to ensure homogenous mixing. After
mixing, the samples were allowed to incubate at room temperature for 30 min, and a
8

series of washes by centrifugation at 14,000 rpm was conducted as before. Samples were
prepared with final concentrations of 1.0 µM, 2.0 µM, and 4.0 µM tRNA. And, as with
C12PEI, the washing steps were manipulated in an attempt to achieve high recovery yields
with high purity while maintaining particle stability.

9

Chapter 4. Results
The following data shows results for both C12PEI and tRNA layer experiments.
AuNP- C12PEI samples that were relatively monodisperse, stable in solution, and
repeatable were chosen as candidates for tRNA trials.
The first two sets of graphs depict the effect of addition method of C12PEI on
particle size. The details of interest are the location of the plasmon resonance peak
relative to that of the AuNP stock, along with the distribution dispersity of the size
measurements. Figures 1a & 1b represent addition down the side of the tube, while
Figures 2a & 2b show addition into the cap with immediate vortexing after cap closure.
Similarly, Figure 3 depicts the UV-Vis results for a replication of the “cap-addition”
method.
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Figure 1a
AuNP stock (black), shown with three samples of C12PEI-AuNPs (red,
green, blue) prepared by direct addition.
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Figure 1b
Representative size distributions for C12PEI-AuNP samples prepared by
direct addition.

Figure 2a
AuNP stock (black), shown with three samples of C12PEI-AuNPs (red, green,
blue) prepared by addition to the tube cap.
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Figure 2b
Representative size distributions for C12PEI-AuNP samples prepared by addition
to the tube cap.

Figure 3
AuNP stock (black), shown with three samples of C12PEI-AuNPs (red, green,
blue). Replicated results prepared by addition to the tube cap.

14

The next set of graphs, Figures 4a – 4d, outline the process of fabricating tRNAC12PEI-AuNP conjugates, beginning with AuNP stock solution. First, Figures 4a & 4b
show UV-Vis and DLS characterization after the first coating step. Figures 4c & 4d
represent the subsequent tRNA coating step and the washing process implemented.

Figure 4a
AuNP stock (black), shown with three samples of C12PEI-AuNPs (red, green,
blue). Replicated results prepared by addition to the tube cap, in preparation for tRNA binding.
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Figure 4b
Representative size distributions for C12PEI-AuNP samples prepared by addition
to the tube cap. Same samples as shown in Figure 4a.

Figure 4c
AuNP stock (black), shown with a representative sample of C12PEI-AuNP (red),
and the corresponding sample of tRNA-C12PEI-AuNP (green).
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Figure 4d
tRNA-C12PEI-AuNP sample shown previously in Figure 4c, shown here with
absorbance after a 2nd wash.

Table 1, shown below, summarizes the data found in Figures 1 – 4 above, along
with zeta potential measurements, and AuNP recovery yield.
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Sample
Type

Original
Sample
Conc.

AuNP

14.8 nM

519

0.5 mM a
0.5 mM b
1.0 mM a
1.0 mM b
2.0 mM a
2.0 mM b
0.5 mM
1.0 mM
2.0 mM
14.8 nM
2.0 mM
2.0 mM
2.0 mM
1 µg/µL
1 µM
2 µM
4 µM

AuNPC12PEI

AuNPC12PEI
AuNP
AuNPC12PEI

tRNA

AuNPC12PEItRNA
(crude)

AuNPC12PEItRNA
(1st wash)

1 µM
2 µM
4 µM
1 µM
2 µM
4 µM

Absorbance
(AU)

Zeta
Potential
(mV)

Size
DLS
(d.nm)

%
Recovery

0

0.05943

-47.4

14.39

n/a

533

14

0.06407

44.1

87.55

107.5

524
531
526
525
525
526
527
527
520
523
523
523
259
259
258
259
257,
528
258,
529
259,
529
257,
528
257,
529
258,
529

5
12
7
6
6
7
8
8
0
3
3
3
n/a
n/a
n/a
n/a

0.04982
0.05526
0.05740
0.04908
0.04632
0.03937
0.03366
0.02788
0.05992
0.03304
0.02691
0.03227
0.48187
0.02095
0.04484
0.08882
0.04377,
0.02419
0.05169,
0.02499
0.07667,
0.02898
0.02953,
0.02126
0.04491,
0.02770
0.05626,
0.03950

39.5
46.8
41.3
44.1
43.2
n/a
n/a
n/a
n/a
59.7
55.9
58.0
n/a
n/a
n/a
n/a

28.09
54.48
28.67
30.13
26.71
n/a
n/a
n/a
n/a
25.85
25.46
24.11
n/a
n/a
n/a
n/a

83.6
92.8
96.3
82.4
77.7
56.5
48.3
40.0
n/a
89.1
71.6
85.1
n/a
n/a
n/a
n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

20.0

n/a

n/a

25.0

n/a

n/a

30.0

(nm)

(nm)

8
9
9
8
9
9

Table 1
UV-Vis, zeta potential, size, and AuNP recovery yield corresponding to particle
description and concentration. AuNP-C12PEI concentrations denoted by (a) were prepared by
direct addition, and those denoted by (b) were prepared by addition to the tube cap. For AuNPC12PEI-tRNA samples, both
wavelengths and their corresponding absorbances are given,
with the first corresponding to tRNA and the second corresponding to AuNP signature peaks.
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Finally, based upon fluorescence measurements, the data leading to the number of
C12PEI units per AuNP for two parallel samples are shown below in Table 2, with an
average of 258.1 C12PEI units per AuNP.

Sample
1
2

[C12PEI]
Conjugated (nM)
1155.68
1480.02

[AuNP]
Recovered (nM)
5.25
5.00

C12PEI per
AuNP
220.1
296.0

Table 2
Quantity of C12PEI units per AuNP ([C12PEI] during incubation was 1.0 mM)
shown with recovery concentration of AuNP and concentration of conjugated C12PEI from
fluorescence measurements.
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Chapter 5: Discussion
As reported above, successful preparation of AuNP-C12PEI conjugates were
achieved. Repeatable samples were synthesized at a final concentration of 2.0 mM, with a
shift in peak absorbance of approximately 4 nm that corresponded to a particle size of
approximately 26.5 nm. AuNP-C12PEI conjugates were determined to be stable in
aqueous solution with a zeta potential greater than +40.0 mV. Additionally, the number
of C12PEI units that can be conjugated to a single AuNP, following the protocol for a
final C12PEI concentration of 1.0 mM, was determined to be approximately 258. By
adjusting the synthetic procedure to include addition of NaCl, the electrostatic repulsion
between neighboring PEI branches could be diminished, potentially allowing for a tenfold increase in C12PEI units per AuNP.
Although unrepeated, AuNP-C12PEI-tRNA conjugates were also achieved.
Samples were synthesized at a final concentration of 1.0 µM, 2.0 µM, and 4.0 µM,
corresponding to a shift in peak absorbance of approximately 5 nm from the previous
layer of C12PEI. tRNA coverage was confirmed by a zeta potential near -5.0 mV.
Despite preparation of several successful samples, implementing a successful
centrifugation and washing procedure proved difficult and resulted in low repeatability.
In an effort to minimize contamination by unconjugated reagent (i.e. C12PEI, tRNA),
samples were often subjected to long periods of centrifugation at maximum speed. Due to
the strong covalent bond at the gold surface with C12PEI, extended centrifugation showed
minimal observed effects on AuNP-C12PEI conjugates. However, the electrostatic
20

interactions between tRNA and C12PEI, though relatively strong, were observed to be
sensitive to the dense packing that occurs in the pellet during centrifugation. An example
of this type of sample degradation due to washing can be seen above in Figure 4d.
In light of this observation, extensive washing may not be necessary in order to
remove unconjugated reagent from crude samples to an acceptable degree. Elbakry et al.
report adequate purification after 2 – 3 washings for PEI, and as few as 1 wash for RNA.8
When compared with their results, the procedure above was found to eliminate the
majority of excess reagent after a similar degree of washing. As such, it may be more
effective to adopt a purification protocol that requires several washes of shorter time
intervals, rather than fewer washes of longer time intervals. In the future, a centrifugation
procedure such as this may allow for syntheses that are more repeatable and usable.
Additionally, it is possible that centrifugation may be bypassed altogether by developing
a dialysis-based purification method. Another alternative may be to develop two stable
half-systems that could be integrated without the need to remove unreacted reagent.
In order to build upon the findings of this project, repeatable sample preparations
that are accurately and quantitatively characterized must be obtained. After confirming
the success of the tRNA conjugation protocol, the next step should involve establishing a
procedure for addition of the final outer layer of polymer along with the targeting moiety.
Upon satisfactory completion of the synthetic portion of the project, in vitro cell studies
should be completed to observe the transfection and gene knockdown efficiency of
AuNP-C12PEI-siRNA conjugates against a gene target, like RRM2, in cancerous tissues.
21
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